Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEn-1124 in Acute Respiratory Distress Syndrome (ARDS)
NCT05795465Phase 2Recruiting
- Sponsor
- GEn1E Lifesciences
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GEN-1124 in acute respiratory distress syndrome (ARDS), sponsored by GEn1E Lifesciences. Started Apr 2023; status: recruiting.
02
Drugs
GEN-1124
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05795465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795465.